EDNRB and ovarian carcinoma: Although other cancers are also approved, this study focuses on metastatic melanoma, platinum-resistant ovarian cancer and pancreatic cancer, cancers in which ETBR is either highly expressed [101,131] or known to correlate with poorer survival [85].